GlassScriptPhysician profile
Brittney Viar
NPI 1619368727
$4,743.05
in general payments reported to CMS, 2019-2025
23 companies · $884 in 2025
The $884 reported for 2025 was more than what 81% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $951 · 2022: $909 · 2023: $1,143 · 2024: $855 · 2025: $884.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,718 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,718.38 |
| Education | $163.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $804.78 | 2021-2025 | |
| Lilly USA, LLC | $702.92 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Abbvie INC. | $691.35 | 2021-2025 | |
| Janssen Biotech, INC. | $585.90 | 2021-2025 | Tremfya, Stelara, Simponi |
| Genzyme Corporation | $357.60 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $277.40 | 2023-2024 | Sotyktu |
| Ucb, INC. | $276.23 | 2021-2025 | Bimzelx, Cimzia |
| Leo Pharma INC. | $132.63 | 2021-2023 | Adbry |
| Amgen INC. | $128.55 | 2023-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $126.30 | 2021-2025 | |
| Incyte Corporation | $106.94 | 2024 | Opzelura |
| Pfizer INC. | $78.47 | 2021-2023 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $65.18 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $58.32 | 2021-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $57.99 | 2024-2025 | Seysara |
| Arcutis Biotherapeutics, INC. | $51.68 | 2023-2025 | Zoryve |
| Genentech USA, INC. | $43.18 | 2022 | |
| Dermavant Sciences, INC. | $38.62 | 2023-2024 | Vtama |
| Smith+Nephew, INC. | $35.82 | 2021-2023 | Collagenase Santyl |
| Botanix Sb INC | $20.63 | 2025 | Sofdra |
| Paratek Pharmaceuticals, INC. | $19.95 | 2024 | Nuzyra |
| Organon LLC | $12.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittney Viar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.